Nektar Therapeutics to sell Alabama facility to Ampersand
The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
bovnews1d
Piper Sandler Issues Overweight Rating for Nektar Therapeutics (NKTR) Stock
On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...
Fintel on MSN1d
Piper Sandler Initiates Coverage of Nektar Therapeutics (NKTR) with Overweight Recommendation
Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...
The Pharma Letter1d
Nektar sells its PEGylation reagent manufacturing business
California, USA-based biotech Nektar Therapeutics’ (Nasdaq: NKTR) shares closed up more than 8% at $1.33 yesterday after it ...
Nektar to sell its Huntsville, Alabama facility to Ampersand Capital for $90M
Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...
Nektar Therapeutics Sells Manufacturing Facility for $90M
The latest update is out from Nektar Therapeutics ( (NKTR) ).
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...
FiercePharma1d
Nektar pads wallet with $90M manufacturing plant sale to Ampersand
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...